Maxim Group analyst Anthony Vendetti has maintained their neutral stance on JYNT stock, giving a Hold rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anthony Vendetti has given his Hold rating due to a combination of factors influencing The Joint Corp.’s current financial and operational situation. The company’s third-quarter revenue aligned with expectations, indicating some stability, but the decline in system-wide comparable sales and the reduction in sales guidance for 2025 reflect ongoing challenges. Additionally, while the company is making strides in refranchising and cost-saving measures, these efforts are accompanied by uncertainties regarding the sale and restructuring of corporate-owned clinics.
Despite having a solid cash position and no debt, which reduces the need for additional capital, the macroeconomic pressures and the slow pace of refranchising are limiting near-term growth prospects. The transition to a full franchise model is progressing, but the decrease in total clinics year-to-date and the weaker sales performance present concerns. Until there is more clarity on these transitional dynamics and macroeconomic conditions improve, the potential for significant upside remains limited, justifying the Hold recommendation.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $8.00 price target.
JYNT’s price has also changed moderately for the past six months – from $9.940 to $7.670, which is a -22.84% drop .